Nita K F Wienholtz, Casper E Christensen, Thien P Do, Lith E W Frifelt, Josefin Snellman, Cristina L Lopez-Lopez, Alexander Egeberg, Jacob P Thyssen, Messoud Ashina
IMPORTANCE: Treatment of erythema and flushing in rosacea is challenging. Calcitonin gene-related peptide (CGRP) has been associated with the pathogenesis of rosacea, raising the possibility that inhibition of the CGRP pathway might improve certain features of the disease. OBJECTIVE: To examine the effectiveness, tolerability, and safety of erenumab, an anti-CGRP-receptor monoclonal antibody, for the treatment of rosacea-associated erythema and flushing. DESIGN, SETTING, AND PARTICIPANTS: This single-center, open-label, single-group, nonrandomized controlled trial was conducted between June 9, 2020, and May 11, 2021...
April 17, 2024: JAMA Dermatology